WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer
Conclusions: These data revealed that targeting WDR5 suppressed proliferation, enhanced apoptosis, chemosensitivity to cisplatin and immunotherapy in PCa. Therefore, our findings provide insight into OICR-9429 is a multi-potency and promising therapy drug, which improves the antitumor effect of cisplatin or immunotherapy in PCa.
Source: Theranostics - Category: Molecular Biology Authors: Qianghua Zhou, Xu Chen, Haixia He, Shengmeng Peng, Yangjie Zhang, Jingtong Zhang, Liang Cheng, Sen Liu, Ming Huang, Ruihui Xie, Tianxin Lin, Jian Huang Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroschisis Repair | Genetics | Immunotherapy | Molecular Biology | Prostate Cancer | Study